Science Immunology: Children of all ages may be vaccinated against the new crown, including babies!

The novel coronavirus has infected hundreds of millions of people around the world since its outbreak in 2019, causing more than 3.
5 million deaths
.

In order to control the spread of SARS-CoV-2, various new crown vaccines have been put on the market one after another.

In the early stage of the new crown pandemic, due to the low infection rate and incidence of SARS-CoV-2, the child SARS-CoV-2 infection vaccine project is not a priority, and whether younger children should be vaccinated and related safety The problem, people still have a lot of questions
.

As of the picture, a variety of children's new crown vaccines have begun to show signs
.

It is reported that Pfizer's BNT162b2 mRNA vaccine has been approved for adolescents over 12 years old.

Therefore, in order to further verify the preventive benefits of the vaccine against younger children, prevent infants from becoming SARS-CoV-2 virus reservoirs, and protect infants from the virus, including infants in the SARS-CoV-2 Global Pediatric Vaccine Program is important for prevention.
The spread of SARS-CoV-2 in children is extremely important
.

To achieve this goal, Dr.
Kristina De Paris, Professor of Microbiology and Immunology at the University of North Carolina School of Medicine, and Dr.
Sallie Permar, Dean of the Department of Pediatrics at Weill Cornell University, jointly evaluated the Moderna mRNA vaccine and a protein-based vaccine candidate ( Protein -3M-052-SE ) safety and immunogenicity
.

And published the research results in " Science Immunology " magazine

Protein-3M-052-SE Science Immunology

In order to evaluate the preventive effect of the SARS-CoV-2 infant vaccine, the researchers immunized 2.
2-month-old rhesus monkey babies (equivalent to 9-month-old human babies) at the National Primate Research Center in California, and monitored them daily An adverse reaction occurred
.

Studies have found that these two vaccines are safe and neither induce a systemic Th2 response

Picture evaluation of the immunogenicity of two SARS-CoV-2 vaccines in infant rhesus monkeys
.

Subsequently, the researchers evaluated the immune response induced by the infant vaccine within 22 weeks.
The IgG-binding antibody in the animal's blood persisted and was able to recognize the spike protein(s) on the surface of the new coronavirus
.

Interestingly, the s protein receptor binding domain (RBD) of SARS-CoV-2 can also be detected in animal saliva, which is similar to the immune response of humans infected with SARS-CoV-2

Not only that, the study found that the neutralizing antibody kinetics induced by the two vaccines were consistent with the plasma binding antibody kinetics and persisted during the study
.

As we all know, neutralizing antibodies play an important role in virus clearance and can be used to protect or treat viral diseases
.

Virus-specific neutralizing antibodies induced by infection or vaccination have the ability to block viral infections

However, the level and effect of SARS-CoV-2 specific neutralizing antibodies are not yet clear
.

Therefore, this study uses a safe and sensitive method based on pseudovirus (PsV)-lentiviral vector neutralization analysis to evaluate the effectiveness of the vaccine

This latest study found that in the 22nd and 18th weeks after receiving the second immunization, the antibody titer of the pseudovirus (PsV) of the Protein-3M-052-SE vaccine group still exceeded 103, and the mRNA-LNP vaccine The group exceeds 102

All in all, this study shows that S-2P mRNA-LNP and Protein-3M-052-SE vaccines may have potential tolerability and high immunogenicity in infants, which provides a new vaccine for SARS-CoV-2 in infants.

Original source:

Original source:

Carolina Garrido, et al.
SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques .
Science Immunology 15 Jun 2021: Vol.
6, Issue 60, eabj3684.

SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques in this message